Although ABT-737 is the most potent and selective small-molecule Bcl-2 inhibitor, it is not very effective against cancer cells that harbor high levels of Mcl-1, such as breast, lung, and melanoma cells [24]. This evidence concerns the gene MCL1 and melanoma.